British government officials are expressing concern that advances in artificial intelligence (AI) could enable terrorists to engineer highly dangerous biological agents, potentially triggering a new pandemic. The prospect has prompted consideration of stricter regulations on the commercial sale of synthetic DNA, which is widely used in legitimate scientific and medical research but could be exploited to create biochemical weapons.

Experts warn that AI's rapid development has significantly lowered the barriers to designing harmful pathogens. Unlike before, when creating a biological weapon required advanced technical expertise, AI systems can now assist users in developing pathogens that are more contagious, induce more severe symptoms, and resist existing treatments. Once a pathogen’s DNA sequence is computationally generated, it could be synthesized in a laboratory and weaponized for an attack with potentially devastating consequences.

Government ministers have voiced fears that a deliberately released, highly infectious agent engineered with the help of AI could trigger a health crisis similar to the Covid-19 pandemic. The coronavirus outbreak, which began in late 2019, has long been subject to speculation including theories that it originated from a laboratory leak at China’s Wuhan Institute of Virology.

Last month, CEOs of leading AI companies wrote to U.S. lawmakers urging tighter controls on synthetic DNA sales. They argued that AI tools now surpass the expertise of PhD-level virologists in designing biological threats, increasing the risk of misuse by malicious actors. Similar concerns have been raised in the United Kingdom, where national security and technology officials have been assessing the risks associated with emerging biotechnologies.

Currently, there is no legal obligation in the UK for laboratories that produce synthetic DNA to verify the identity or motives of their customers. In October 2024, voluntary guidelines were issued recommending that labs screen orders for "red flags" and confirm legitimate reasons for purchasing DNA sequences. However, these guidelines do not impose mandatory compliance, leaving a regulatory gap.

A spokesperson for the UK government emphasized that the country was among the first to establish screening guidance for synthetic DNA transactions but acknowledged the need for ongoing vigilance. “We are monitoring the risks posed by emerging technologies closely, actively weighing at all times what more may be needed,” the official said.

As technology advances, policymakers face the challenge of balancing scientific innovation with safeguards against potential misuse, particularly in areas where AI and biotechnology intersect to create new security risks.